SCHEMBL428015

SCHEMBL428015

C=CCc1cccc2nc(C(N)C(=O)OCC)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
ALDH1A1 P00352 5/20 0.39
L3MBTL1 Q9Y468 4/20 0.38
MAPK1 P28482 2/20 0.38
POLB P06746 3/20 0.37
GLA P06280 1/20 0.37
MAPT P10636 4/20 0.37
PRNP P04156 1/20 0.37
ELANE P08246 1/20 0.36
MEN1 O00255 6/20 0.36
KMT2A Q03164 6/20 0.36
PKM P14618 4/20 0.36
LMNA P02545 3/20 0.36
NPSR1 Q6W5P4 3/20 0.36
HTT P42858 2/20 0.36
USP2 O75604 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HIF1A Q16665 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425787 0.83 HSD17B10 (0.39) KDM4EHSD17B10ALDH1A1L3MBTL1MAPK1
SCHEMBL429986 0.82 ALDH1A1 (0.45) KDM4EHSD17B10ALDH1A1L3MBTL1MAPK1
SCHEMBL433128 0.80 MAPT (0.38) KDM4EHSD17B10ALDH1A1L3MBTL1POLB
SCHEMBL428174 0.79 ALDH1A1 (0.38) KDM4EHSD17B10ALDH1A1L3MBTL1POLB
SCHEMBL426942 0.79 PTGS2 (0.42) KDM4EHSD17B10ALDH1A1L3MBTL1POLB
SCHEMBL28524131 0.77 MEN1 (0.39) KDM4EHSD17B10ALDH1A1POLBMAPT
SCHEMBL8852131 0.71 MGAM (0.49) KDM4EHSD17B10ALDH1A1L3MBTL1MAPT
SCHEMBL28524128 0.71 KDM4E (0.41) KDM4EHSD17B10ALDH1A1MAPTMEN1
SCHEMBL10212024 0.69 MEN1 (0.40) KDM4EHSD17B10ALDH1A1MAPK1POLB
SCHEMBL16620770 0.69 ALDH1A1 (0.48) KDM4EHSD17B10ALDH1A1MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022056-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS BENTLEY JONATHAN (IT) 2012-01-26 US disclosed
EP-1786822-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS GLAXO GROUP LIMITED (GB) 2007-05-23 EP disclosed
WO-2006024517-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS GLAXO GROUP LIMITED (GB) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022056-A1 FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS GABBR1, GABRQ, GABRE KDM4E 3168/4885HSD17B10 1006/4885ALDH1A1 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.